Pre-Conference Day
Monday, June 10

Investment & Business Development Focus Day

With current market headwinds, it is essential that cell therapy leaders are able to juggle limited cash runways and identify which programs to prioritize, all while maintaining efficient speed-to-clinic and market for safe and effective therapies.

Beyond Oncology Bootcamp Day

With exciting clinical results demonstrated in lupus, MS and many other autoimmune conditions, the cell therapy community are looking beyond treating purely cancer indications more than ever.

Understanding the State of Play for Allogeneic BioPharma Investment

10:00 am Forecasting the Landscape for Allogeneic Cell Therapies Over the Next Few Years to Help Guide Business Decisions

Synopsis

  • Taking an analytical approach to understanding current and future trends in investment into allogeneic therapies
  • Assessing market dynamics and trends that will impact growth and adoption
  • Building strategic models to plan for an evolving allogeneic cell therapy space

10:30 am Demystifying Key Investment Criteria for the Allogeneic Cell Therapy Space

Synopsis

  •  Clarifying essential factors investors evaluate when considering allogeneic deals
  • Understanding key data and milestones investors seek at different funding stages
  • Building an investment case by aligning critical investment criteria

11:00 am Morning Break & Networking

Building Capital & Support to take Your Biotech Company to the Next Level

11:30 am Exploring Partnership Models to Optimize Investment in Allogeneic Cell Therapies

Synopsis

  • Structuring deals to balance risks and rewards between industry and investors
  • Understanding different partnership models to find the best fit for you
  • Case studies of innovative partnership models to fund allogeneic cell therapy development

12:00 pm Turning Your Unique Concept into a Successful Biotech Start-Up

Synopsis

  • When is the right time to take the leap from researcher to entrepreneur?
  • How do take your idea and turn it into a real biotech company?
  • Fundraising strategies for new startups to begin building a cash runway and prepare your new biotech for success

12:30 pm Lunch Break

1:30 pm Panel: Meet the Investors – Your Questions Answered

Synopsis

  • A unique panel discussion with decision makers from groups who have invested in allogeneic biotechnology companies
  • An opportunity for you to ask your burning questions when it comes to best practices for obtaining investment
  • Learn how to tailor and advance your pipeline to align with investors’ future goals

2:30 pm Close of Pre-Conference Day

Tackling Autoimmune Conditions with Scalable & Effective Therapies

10:00 am Unlocking the Potential of Allogeneic Cell Therapies for Inflammatory Disease

  • Omid Veiseh Associate Professor, CPRIT Scholar in Cancer Research, Rice University

Synopsis

  • Exploring a novel allogeneic cell therapy platform and its applications for ARDs and other inflammatory indications
  • Diving into the details of an innovative therapeutic platform, enabling improved spatial and temporal control
  • Discussing future directions for translating novel research into clinical applications

10:30 am Combatting Infectious Disease with Allogeneic Invariant NK Cell Therapies

Synopsis

  • Delving into MiNK Therapeutics’ approach to serious infectious diseases, harnessing the potential of their allogeneic cell therapy platform
  • Investigating the unique benefits of iNK cells, including enhanced spatial and temporal control
  • Translating MiNK Therapeutics’ research into clinical applications for infectious diseases

11:00 am Morning Break & Networking

Reviewing Clinical Trial Strategies & Lessons Learned to Streamline Your Transition to the Clinic

11:30 am Applications for Allogeneic Cell Therapies for Rare & Orphan Diseases

  • Lauren Bor Process Development Manager, TCBiopharm New!

Synopsis

  • Evaluating the promise of “off-the-shelf” cells for small patient populations
  • Reviewing the pre-clinical and clinical landscape across rare disease indications
  • Building the investment case for allogeneic cell therapies in rare diseases

12:00 pm Considerations for Developing Allogeneic Therapies in Non-Cancer Settings

  • Wonjong Si Associate Director - Cell Therapy & Platform Process, Bayer

Synopsis

  • Understanding distinctions in endpoints for non-oncology trials
  • Differentiating trials to accommodate chronic and non-fatal indications
  • Overcoming unique challenges to demonstrate clinical benefit in new areas

12:30 pm Lunch Break

1:30 pm Panel: The Future of Allogeneic Cell Therapies in Autoimmune Indications & Beyond

Synopsis

  • Assessing promise for allogeneic cell therapies that may be on the horizon
  • Comparing development pathways across various non-autoimmune indications
  • Identifying future indications with the most potential for allogeneic benefit

2:30 pm Close of Pre-Conference Day